Male reporoductive

Male Reproductive Health Study Notes

Overview

  • This guide covers important topics related to male reproductive health, focusing on:
      - Testicular Cancer
      - Benign Prostatic Hyperplasia (BPH)
      - Prostate Cancer
      - Erectile Dysfunction (ED)

Testicular Cancer

Incidence and Significance

  • Statistics:
      - Represents 1% of all male cancers.
      - Major cancer incidence in men aged 15-35 years.
      - Recognized as the most curable type of cancer.

Risk Factors

  • Cryptorchidism: Undescended testicles increase risk.

  • Family History: Genetics play a role.

  • Race: Higher incidence in Caucasian men.

  • HIV Infection: Associated with increased risk.

Types of Germ Cell Tumors (95% of cases)

  1. Seminomas:
       - Arise from immature germ cells.
       - Characteristics: Slow-growing, nonaggressive.
       - Treatment: Easily cured with radiation.

  2. Nonseminomas:
       - Arise from mature germ cells.
       - Characteristics: More aggressive than seminomas.
       - Treatment: Typically managed with surgery.

Early Clinical Manifestations

  • Enlargement of Testicle: Initial symptom observed.

  • Painless Mass: Noted in the absence of discomfort.

  • Discomfort Symptoms (30-40% of cases):
      - Dull ache in the groin.
      - Sensation of heaviness.

Late Clinical Manifestations

  • Possible acute pain may develop.

  • Metastatic Spread Symptoms:
      - Cough.
      - Hemoptysis (coughing up blood).
      - Swelling of lower extremities.
      - Back pain.
      - Dizziness.

Benign Prostatic Hyperplasia (BPH)

Definition and Overview

  • Definition: Nonmalignant enlargement of the prostate.

  • Cell Type Increases:
      - Epithelial Cells: Increase by 11.9%.
      - Smooth Muscle Cells: Increase by 38.8%.
      - Stromal Cells: Increase by 38.6%.

  • Results in Lower Urinary Tract Symptoms (LUTS).

Risk Factors

  • Non-modifiable:
      - Age
      - Family History
      - Race/Ethnicity

  • Modifiable:
      - Obesity and Metabolic Syndrome
      - Caffeine Consumption
      - Levels of Physical Activity

Etiology of BPH

  • Hormonal Imbalance:
      - Role of Testosterone and Estrogen (Estradiol).

  • DHT Accumulation:
      - DHT: Dihydrotestosterone is formed from testosterone via the enzyme 5 alpha-reductase.

  • Importance:
      - Acts on skin (causing acne).
      - Influences hair growth (body hair vs. scalp).
      - Stimulates the growth of prostate cells.

Clinical Manifestations of BPH

  • Symptoms:
      - Frequency and Urgency to urinate.
      - Increased urination time.
      - Dribbling at the end of urination.
      - Delay in the initiation of urination.
      - Reduction in force of urinary stream.
      - Nocturia: Urination during the night.
      - Inability to completely empty the bladder.
      - Risk of Urinary Tract Infection (UTI).

Complications

  • Resulting complications may include:
      - Obstruction of urinary flow.
      - Development of UTIs.
      - Potential Renal Issues due to prolonged obstruction.

Treatment of BPH

  • Observation: For mild symptoms (watchful waiting).

  • Moderate Symptoms: Drug therapy.
      - 5-alpha Reductase Inhibitors
      - Alpha1-Adrenergic Antagonists

  • Severe Symptoms: May require invasive surgical options.

Specific Medications

  1. 5-alpha Reductase Inhibitors:
       - Finasteride (Proscar):
         - Indicated for mechanical obstruction of urethra.
         - Mechanism of Action (MOA): Blocks conversion of testosterone to DHT; decreases epithelial tissue size.
         - Adverse Effects: Impotence, decreased libido (5-10%), gynecomastia (breast tissue enlargement). Decreases prostate-specific antigen (PSA) levels.
       - Dutasteride (Avodart):
         - Similar action as finasteride, but affects both alpha 1 & 2 receptors.

  2. Alpha1-Adrenergic Antagonists:
       - Tamsulosin (Flomax):
         - Relaxes smooth muscle in the prostate, alleviating dynamic obstruction of the urethra.
         - Adverse Effects: Generally well tolerated, but may cause abnormal ejaculation.

  3. Combination Therapy:
       - Dutasteride + Tamsulosin (Jalyn):
         - FDA approved for BPH; evidence supports superiority over single-agent therapies.

Prostate Cancer

Overview

  • Incidence:
      - Most common cancer among men in the U.S.
      - 2nd leading cause of cancer-related death.

  • Demographics:
      - Highest incidence in African-American men; lowest in Asians and Native Americans.
      - Incidence rises sharply after age 50.
      - Over 80% of cases present in men over 65 years.

Risk Factors

  • Age: Increased risk with age.

  • Ethnicity: African-American men are at highest risk.

  • Familial Tendency: Genetic factors at play.

  • Diet: High-fat diets contribute to risk.

Clinical Manifestations

  • Early: Symptoms similar to BPH.

  • Later: Metastasis primarily affecting:
      - Bones
      - Lungs

  • Prognosis: Depends on the cancer stage; early detection improves outlook.

Controversy Surrounding Prostate Cancer

  • Prevalence vs. Clinical Relevance: Many diagnosed cancers may not become harmful within a man's lifetime.

  • Most cases progress slowly, leading to death from unrelated causes.

  • PSA Screening: Widely used before evidence confirmed its efficacy.
      - Benefits: Some survival benefits noted.
      - Harms: Many unnecessary biopsies, treatments. Side effects include:
        - Erectile Dysfunction
        - Urinary Incontinence
        - Bowel problems.

Prognostic Factors

  • Severity Indicators:
      - Gleason Score: Higher score equates to worse prognosis.
      - Tumor Volume: Larger volume indicates increased risk.
      - PSA Levels: Higher and quicker rises suggest worse outcomes.
      - Detection Method: PSA vs. Digital Rectal Exam (DRE).

Erectile Dysfunction (ED)

Definition

  • Also known as Impotence.

  • Defined as the inability to achieve or maintain an erection sufficient for satisfactory sexual intercourse.

  • Significance: Affects approximately 30 million men in the U.S.; frequently associated with chronic illnesses.

Classification of ED

  1. Primary ED:
       - Rare; lifelong inability to achieve an erection.
       - Causes: Severe psychiatric problems, early vascular trauma.

  2. Secondary ED:
       - More common; develops in a person who previously had normal erections.
       - Causes can include organic and psychogenic factors.

Etiology of Secondary ED

  • Organic Causes:
      - Peripheral Vascular Disease: Issues like arterial insufficiency, excessive venous drainage, sedentary lifestyle.
      - Endocrine Problems: Hormonal imbalances.
      - Medications: Antidepressants, antihypertensives.

  • Psychogenic Causes:
      - Conditions such as depression, performance anxiety, and strained relationships may contribute.

Physiology of Normal Erection

  • Mechanism involves increased parasympathetic nervous system (PNS) activity and nitric oxide release:
      - Leads to activation of cyclic GMP (cGMP).
      - Results in relaxation of arteries and smooth muscles, increasing inflow and reducing outflow, causing engorgement and erection.
      - Phosphodiesterase Type 5 (PDE-5) breaks down cGMP, ending the erection.

PDE-5 Inhibitors

  • Prototype: Sildenafil (Viagra).
      - MOA: Inhibits PDE-5, thereby increasing and sustaining cGMP levels, enhancing natural sexual response.

  • Indications:
      - Relief of ED.
      - Management of pulmonary arterial hypertension.
      - BPH treatment.

Usage and Timing of Sildenafil

  • Timing: Taken up to 4 hours before sexual activity (onset: 30-60 minutes).

  • Adverse Effects: Common effects include headaches (16%), flushing (10%), dyspepsia (7%).

  • Cautions: Contraindicated with nitrates; monitor for hypotension.

  • Safety Issues:
      - Do not combine with nitrates.
      - If experiencing chest pain or other signs of heart attack, seek emergency help immediately.
      - Report sudden loss of vision or hearing.
      - Limit to one dose per day. Priapism (prolonged and painful erection lasting more than 4 hours) is a medical emergency.

References

  • Lynn Kelso DNP, APRN, FCCM, FAANP

  • Capriotti, T. M. & Frizzell, J. P. (2015). Pathophysiology: Introductory Concepts and Clinical Perspectives. FA Davis Company.

  • Nickel JC. (2004). Comparison of clinical trials with finasteride and dutasteride. Rev Urol, 6 Suppl 9(Suppl 9):S31-S39.

  • Dimitropoulos, K. & Gravas, S. (2016). Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia. Therapeutic Advances in Urology, 8(1), 19-28.

  • Links to further information on risk factors and epidemiology of testicular germ cell tumors and prostate cancer.